BR112022017998A2 - Formulações de liberação controlada compreendendo drotaverina ou sal da mesma - Google Patents

Formulações de liberação controlada compreendendo drotaverina ou sal da mesma

Info

Publication number
BR112022017998A2
BR112022017998A2 BR112022017998A BR112022017998A BR112022017998A2 BR 112022017998 A2 BR112022017998 A2 BR 112022017998A2 BR 112022017998 A BR112022017998 A BR 112022017998A BR 112022017998 A BR112022017998 A BR 112022017998A BR 112022017998 A2 BR112022017998 A2 BR 112022017998A2
Authority
BR
Brazil
Prior art keywords
drotaverine
salt
controlled release
release formulations
provides
Prior art date
Application number
BR112022017998A
Other languages
English (en)
Inventor
Paul Berlia Sushma
Berlia Nishant
Singh Gurvinder
Singh Bhandari Sunder
Diwan Anupama
Original Assignee
Paul Berlia Sushma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul Berlia Sushma filed Critical Paul Berlia Sushma
Publication of BR112022017998A2 publication Critical patent/BR112022017998A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Abstract

FORMULAÇÕES DE LIBERAÇÃO CONTROLADA COMPREENDENDO DROTAVERINA OU SAL DA MESMA. A presente invenção fornece formulações de liberação controlada compreendendo drotaverina ou sal da mesma ou agentes ativos semelhantes que são propensos à degradação oxidativa/hidrolítica. A invenção fornece formulações de liberação controlada uma ou duas vezes ao dia de drotaverina ou sal da mesma que evita flutuações dos níveis plasmáticos, reduz a carga de pílulas e os efeitos colaterais devido ao cronograma de dosagem simplificado, melhorando assim a adesão do paciente. A invenção também fornece métodos de preparação de formulações de liberação controlada de Drotaverina ou sal da mesma. A invenção fornece ainda formulações de liberação controlada de drotaverina ou sal da mesma para tratar pelo menos um sintoma de distúrbios gastrointestinais, biliares, urológicos e ginecológicos caracterizados por condições espásticas de músculos lisos em um indivíduo.
BR112022017998A 2020-03-09 2021-03-09 Formulações de liberação controlada compreendendo drotaverina ou sal da mesma BR112022017998A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202011010072 2020-03-09
PCT/IB2021/051942 WO2021181262A1 (en) 2020-03-09 2021-03-09 Controlled release formulations comprising drotaverine or salt thereof

Publications (1)

Publication Number Publication Date
BR112022017998A2 true BR112022017998A2 (pt) 2022-10-25

Family

ID=75497970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017998A BR112022017998A2 (pt) 2020-03-09 2021-03-09 Formulações de liberação controlada compreendendo drotaverina ou sal da mesma

Country Status (15)

Country Link
US (1) US20230018600A1 (pt)
EP (1) EP4117638A1 (pt)
JP (1) JP2023525202A (pt)
KR (1) KR20220151678A (pt)
CN (1) CN115279346A (pt)
AU (1) AU2021235395A1 (pt)
BR (1) BR112022017998A2 (pt)
CA (1) CA3174747A1 (pt)
CL (1) CL2022002431A1 (pt)
CO (1) CO2022013429A2 (pt)
CR (1) CR20220506A (pt)
IL (1) IL296132A (pt)
JO (1) JOP20220209A1 (pt)
MX (1) MX2022011196A (pt)
WO (1) WO2021181262A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023152674A1 (en) * 2022-02-09 2023-08-17 Berlia Sushma Paul A pharmaceutical combination of antispasmodic and anxiolytic agent
US20240091217A1 (en) 2022-07-29 2024-03-21 Sushma Paul BERLIA Stable pharmaceutical oral liquid formulation of an antispasmodic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225779B1 (en) * 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
RU2199308C1 (ru) 2001-12-24 2003-02-27 Закрытое акционерное общество "Брынцалов-А" Раствор для инъекций нош-бра, обладающий спазмолитическим действием
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
EP2156835A1 (en) 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
WO2012159964A1 (en) 2011-05-20 2012-11-29 Chinoin Private Co Ltd Pharmaceutical composition comprising drotaverine
JP2014516080A (ja) * 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
RU2535049C1 (ru) 2013-07-11 2014-12-10 Общество с ограниченной ответственностью "КОМПАНИЯ "ДЕКО" Способ получения стабилизированной субстанции дротаверина гидрохлорида
WO2016075617A1 (en) 2014-11-11 2016-05-19 Dr. Reddys Laboratories Limited Fixed dose pharmaceutical formulations of analgesic and anti-spasmodic drugs
EP3484456A4 (en) * 2016-07-17 2020-03-18 Mapi Pharma Limited RETARD PHARMACEUTICAL FORMS OF PREGABALIN
EP3520781A1 (en) * 2018-02-05 2019-08-07 Adamed sp. z o.o. A pharmaceutical composition comprising metamizole, drotaverine, and caffeine

Also Published As

Publication number Publication date
CN115279346A (zh) 2022-11-01
JOP20220209A1 (ar) 2023-01-30
CR20220506A (es) 2023-01-17
EP4117638A1 (en) 2023-01-18
WO2021181262A1 (en) 2021-09-16
MX2022011196A (es) 2022-09-19
KR20220151678A (ko) 2022-11-15
AU2021235395A1 (en) 2022-09-29
CA3174747A1 (en) 2021-09-16
CL2022002431A1 (es) 2023-03-03
US20230018600A1 (en) 2023-01-19
JP2023525202A (ja) 2023-06-15
IL296132A (en) 2022-11-01
CO2022013429A2 (es) 2022-09-30

Similar Documents

Publication Publication Date Title
Machado et al. Sleep bruxism: Therapeutic possibilities based in evidences
BRPI0520588B8 (pt) uso de composições farmacêuticas para o tratamento de doenças do ouvido interno
Müller et al. Effectiveness of bracing in the treatment of nonosseous restriction of elbow mobility: a systematic review and meta-analysis of 13 studies
BR112022017998A2 (pt) Formulações de liberação controlada compreendendo drotaverina ou sal da mesma
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BRPI0704238A (pt) preventivo da doença de coccidiose e clostrìdica e/ou terapia para a doença de coccidiose e clostridica
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA200971053A1 (ru) Способы лечения кожных язв
BR112016020381A8 (pt) sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina.
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
BR112022015533A2 (pt) Composições e métodos para tratar doenças oculares
PH12020551179A1 (en) Methods for treating mitochondrial disorder
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
BR112021000183A8 (pt) Preparação medicinal para uso externo
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2022014199A (es) Usos y formulaciones de los cannabinoides.